Q
Quidel
Quidel - Immunoassays & Molecular Diagnostics Healthcare Solutions
About Quidel
Quidel Corporation, established in 1979, is a prominent player in the medical diagnostics industry. The company specializes in developing, manufacturing, and marketing diagnostic testing solutions. Quidel's product portfolio includes a wide range of diagnostic tests that are used to detect various diseases and conditions. These products are primarily used by healthcare professionals in hospitals, clinics, and laboratories.
Quidel operates in the global healthcare market, with a strong focus on infectious diseases, reproductive health, bone health, and virology. The company has established itself as a leader in several diagnostic categories, including lateral flow tests, direct fluorescent antibody (DFA) tests, microtiter plate-based tests, fluorescent immunoassays, and molecular diagnostic products.
The company's business model revolves around the development and commercialization of innovative diagnostic tests. Quidel invests heavily in research and development to create new products and improve existing ones. The company generates revenue by selling its diagnostic tests and related products to healthcare providers and institutions. Additionally, Quidel has expanded its product base through strategic acquisitions, further enhancing its market presence and product offerings.
Quidel's recent achievements include the development of a rapid antigen test for detecting COVID-19, which received emergency use authorization from the FDA. This test is notable for being faster, cheaper, and simpler than traditional diagnostic methods, making it a valuable tool in managing the pandemic.
In summary, Quidel Corporation is a key player in the medical diagnostics industry, providing innovative and reliable diagnostic solutions to healthcare professionals worldwide. The company's commitment to research and development, coupled with its strategic acquisitions, has positioned it as a leader in the market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1979
- Headquarters
- San Diego, United States
- Listing
- IPO 1981
- Employees
- 493
- Open positions
- None listed
- Dealroom signal
- 30.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Diabetes, Biotechnology, Oncology, Molecular
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 5 companies, latest May 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | May 2020 | $635K | — | Undisclosed | — |
| IPO✓Exit | Aug 1981 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Quidel is 62K monthly website visits, down 33.3% over the last three months. Quidel's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ortho Clinical DiagnosticsCoupru, FranceOur purpose is to improve and save lives with diagnostics. Watch how - https://t.co/uPL1V6wIc9
→
IM
ImmutopicsSan Clemente, United StatesImmutopics manufactures diagnostic kits for pre-clinical studies in bone and mineral metabolism for human
$5.5Mvaluation
AN
AnDiaTecKornwestheim, Germany
$7.3Mvaluation
BI
BiohelixBeverly, United StatesBiohelix is to improve the quality of healthcare through the development of simple molecular diagnostic tests
$10Mvaluation
DH
Diagnostic HybridsAthens, GreeceQuidel - Immunoassays & Molecular Diagnostics Healthcare Solutions
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
HHS Administration for Strategic Preparedness and Response
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quidel on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quidel’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.